Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis

  title={Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis},
  author={Sivakumar Chinnadurai and Christopher J Fonnesbeck and Kristen M Snyder and Nila A. Sathe and Anna Morad and Frances E. Likis and Melissa McPheeters},
CONTEXT: Infantile hemangiomas (IH) may be associated with significant functional impact. OBJECTIVE: The objective of this study was to meta-analyze studies of pharmacologic interventions for children with IH. DATA SOURCES: Data sources were Medline and other databases from 1982 to June 2015. STUDY SELECTION: Two reviewers assessed studies using predetermined inclusion criteria. DATA EXTRACTION: One reviewer extracted data with review by a second. RESULTS: We included 18 studies in a network… 

Figures and Tables from this paper

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies
Oral propranolol is superior to other treatments in improving response rate of IH and can be used as the first-line therapy for IH children and the Cochrane Collaboration 6 aspects of bias, methodological index for non-randomized studies and the Newcastle–Ottawa Scale are revealed.
Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis
This meta-analysis confirmed that the topical timolol alone was more beneficial on response rate and adverse event than laser, placebo, and observation and the response rate did not differ significantly when comparing the topical Timolol to propranolol.
Infantile Hemangioma: An Updated Review.
Treatment of infantile hemangiomas should be individualized, depending upon the size, rate of growth, morphology, number and location of the lesion (s), existing or potential complications, benefits and adverse events associated with the treatment, age of the patient, level of parental concern, and the physician's comfort level with the various treatment options.
Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls.
  • L. Tiemann, S. Hein
  • Medicine
    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
  • 2020
Systemic and topical β-blockers are effective and safe for use in pediatric patients and considered first-line treatment for both complicated and uncomplicated IHs.
Medical Management of Infantile Hemangiomas: An Update
The clinical features, associations, complications/sequelae and therapeutic approaches for IH are reviewed, focusing on current medical therapy, including propranolol and other oral β-blockers, topical timolol, and corticosteroids.
Central Nervous System Effects of Oral Propranolol for Infantile Hemangioma: A Systematic Review and Meta-Analysis
Despite no statistically significant associations, there were suggestive findings of increased CNS effects and sleep-related risk of propranolol versus non-corticosteroids and in practice, CNS andSleep-related events should be monitored more closely among IH patients treated with oral propr ethanol.
Adverse Drug Reactions Following Propranolol in Infantile Hemangioma
Young children with low body weight were at higher risk for adverse effects of propranolol and younger age,Low body weight and early onset were risk factors for development of severe adverse reactions.
Infantile Hemangiomas of the Lip: Complications and Need for Surgical Intervention
Lip hemangiomas have high rates of complications that seem to be related to lesion morphology and phase of growth.
β-blockers in the treatment of periocular infantile hemangioma.
Oral β-blockers are now the mainstay of treatment for periorbital hemangiomas but still with no consensus on their administration and monitoring, and the topical form or more selective β- blockers may be the solution to minimize side-effects.


Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review
A systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.
Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis.
Propranolol therapy was more clinically effective and more cost-effective than oral corticosteroids in treating IHs, and it also resulted in fewer surgical interventions and demonstrated better tolerance, with minimal adverse effects, compared with oral cortingosteroids.
Propranolol versus Corticosteroids in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis
It appears that propranolol could be an emerging and effective treatment for infantile hemangiomas with fewer side effects, a different mechanism of action, and greater efficacy than current first-line corticosteroid therapy.
Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature
The objective of this study is to critically re‐examine the literature reporting the incidence of infantile hemangiomas to determine if the true incidence is actually known and to more accurately define the incidence and potential impact of this common vascular tumor of infancy.
Propranolol therapy for infantile hemangioma
The reviewed literature suggests that propranolol carries promise as a potential replacement for corticosteroids as first-line therapy or as a part of a multimodal approach.
Propranolol versus Prednisone in the Treatment of Infantile Hemangiomas: A Retrospective Comparative Study
Propranolol appears superior to oral prednisone in inducing more‐rapid and greater clinical improvement in this study and a larger prospective study comparing these two treatment modalities is warranted.
Propranolol for Infantile Hemangioma (PINCH): An Open-label Trial to Assess the Efficacy of Propranolol for Treating Infantile Hemangiomas and for Determining the Decline in Heart Rate to Predict Response to Propranolol
Propranolol is efficacious in patients with IH, with the most pronounced response seen in the first 8 weeks and in infants aged 6 months or younger.
Propranolol for Severe Infantile Hemangiomas: Follow-Up Report
Propranolol administered orally at 2 to 3 mg/kg per day has a consistent, rapid, therapeutic effect, leading to considerable shortening of the natural course of IHs, with good clinical tolerance.
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Although prednisolone showed a faster response rate, propranolol was better tolerated with significantly fewer severe AEs, and both medications show similar efficacy for reducing the area of symptomatic, proliferating IH.
Multicenter prospective study of ulcerated hemangiomas.